EVALUATION OF RABEPRAZOLE EFFICACY WHEN TREATING PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE WITH COMORBID FUNCTIONAL GASTROINTESTINAL DISORDERS
Objective. The objective of this study was to evaluate rabeprazole efficacy when treating patients with gastroesophageal reflux disease (GERD) with comorbid functional gastrointestinal disorders (FGID). Material and Methods. A total of 111 patients with reflux oesophagitis grade A (Los Angeles classification) - 72 females, mean age 41,2±1,2 years - were divided into two different groups based on irritable bowel syndrome (IBS): GERD group (n=46) and GERD & IBS group (n=65). There was no significant difference between the two groups with regard to age, sex or body mass index. All patients were treated with rabeprazole 20 mg once daily for four weeks. Twenty-four-hour intragastric pH monitoring was performed on day 5 after rabeprazole administration. Clinical symptoms (GerdQ questionnaire) and quality of life indicators (SF-36) were estimated at baseline and 4 weeks after its administration. Results. Response rates after 4 weeks of rabeprazole treatment were lower in GERD patients with IBS than in patients without IBS (67,7 % versus 86,9 %, р=0,035). The latent period for rabeprazole was two-fold higher (p<0,0001) and effective rabeprazole duration was 1,3-fold lower (p<0,0001) in GERD & IBS group than in GERD group. Irritable bowel syndrome (OR 3.18; 95 % CI (1,17; 8,67), р=0,035) and functional dyspepsia (OR 3,30; 95 % CI (1,14; 9,55), р=0,040) were predictors of low rabeprazole efficacy in GERD patients.